Cargando…

Pharmacological management of COVID-19 in type 2 diabetes

Evidence suggests that diabetes is one the most relevant comorbidity in affecting the prognosis of COVID-19. Albeit there are no specific trials nor subgroup analysis showing the effect of COVID-19 therapies in patients with diabetes, selected features of this disease and the side effects associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceriello, Antonio, Prattichizzo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052602/ https://www.ncbi.nlm.nih.gov/pubmed/33896714 http://dx.doi.org/10.1016/j.jdiacomp.2021.107927

Ejemplares similares

Variability of risk factors and diabetes complications
por: Ceriello, Antonio, et al.
Publicado: (2021)

Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register
por: Ceriello, Antonio, et al.
Publicado: (2021)

“Inflammaging” as a Druggable Target: A Senescence-Associated Secretory Phenotype—Centered View of Type 2 Diabetes
por: Prattichizzo, Francesco, et al.
Publicado: (2016)

Tackling the pillars of ageing to fight COVID-19
por: Prattichizzo, Francesco, et al.
Publicado: (2021)

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
por: Ceriello, Antonio, et al.
Publicado: (2021)

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target
por: Ceriello, Antonio, et al.
Publicado: (2022)

Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms
por: Sardu, Celestino, et al.
Publicado: (2022)

DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions
por: De Nigris, Valeria, et al.
Publicado: (2021)

One-hour plasma glucose combined with skin autofluorescence identifies subjects with pre-diabetes: the DIAPASON study
por: La Sala, Lucia, et al.
Publicado: (2020)

COVID-19 and diabetes management: What should be considered?
por: Ceriello, Antonio, et al.
Publicado: (2020)

Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications
por: Prattichizzo, Francesco, et al.
Publicado: (2021)

Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes
por: Marfella, Raffaele, et al.
Publicado: (2022)

The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications
por: Testa, Roberto, et al.
Publicado: (2017)

Type 2 Diabetes: How Much of an Autoimmune Disease?
por: de Candia, Paola, et al.
Publicado: (2019)

Effect of time and titer in convalescent plasma therapy for COVID-19
por: de Candia, Paola, et al.
Publicado: (2021)

“Diabetes as a case study of chronic disease management”: Eight years later. The opportunity learned from the COVID-19 pandemic
por: Ceriello, Antonio
Publicado: (2020)

Diabetes, SARS-CoV-2/COVID-19 vaccines and glycemic control: Call for data
por: Ceriello, Antonio
Publicado: (2021)

Diabetes Research and Clinical Practice and the fight against COVID-19
por: Ceriello, Antonio
Publicado: (2022)

Management of hyperglycemia in type 2 diabetes: evidence and uncertainty
por: Esposito, Katherine, et al.
Publicado: (2013)

Antioxidant Anti-Inflammatory Treatment in Type 2 Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2009)

Diabetes, D-dimer and COVID-19: The possible role of glucose control
por: Ceriello, Antonio
Publicado: (2020)

The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2023)

Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability
por: La Sala, Lucia, et al.
Publicado: (2018)

Pharmacological Management of Obese Patients with Type 2 Diabetes amid COVID-19 Pandemic
por: Kow, Chia Siang, et al.
Publicado: (2020)

Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?
por: Giuliani, Angelica, et al.
Publicado: (2017)

Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
por: Blüher, Matthias, et al.
Publicado: (2022)

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
por: La Grotta, Rosalba, et al.
Publicado: (2022)

Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions
por: De Nigris, Valeria, et al.
Publicado: (2017)

Corrigendum to “Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?”
por: Giuliani, Angelica, et al.
Publicado: (2019)

Issues for the management of people with diabetes and COVID-19 in ICU
por: Ceriello, Antonio, et al.
Publicado: (2020)

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
por: Pujadas, Gemma, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

Glucagon and heart in type 2 diabetes: new perspectives
por: Ceriello, Antonio, et al.
Publicado: (2016)

Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes
por: Prattichizzo, Francesco, et al.
Publicado: (2015)

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
por: Schnell, Oliver, et al.
Publicado: (2020)

Type 1 diabetes and cardiovascular disease
por: Schnell, Oliver, et al.
Publicado: (2013)

Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity
por: Garavelli, Silvia, et al.
Publicado: (2020)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Neumiller, Joshua J, et al.
Publicado: (2010)

COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used)
por: Gentile, Sandro, et al.
Publicado: (2020)

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
por: Genovese, Stefano, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4js7f46lipkd4349vep39qimhq